首页> 外文期刊>Emerging microbes & infections. >Analysis of global prevalence of antibiotic resistance in Acinetobacter baumannii infections disclosed a faster increase in OECD countries
【24h】

Analysis of global prevalence of antibiotic resistance in Acinetobacter baumannii infections disclosed a faster increase in OECD countries

机译:对鲍曼不动杆菌感染的全球耐药性流行情况进行分析后发现,经合发组织国家中的耐药性增长更快

获取原文
           

摘要

Acinetobacter baumannii is one of the most challenging nosocomial pathogens due to the emergence and widespread of antibiotic resistance. We aimed to provide the first analysis of global prevalence of antibiotic resistance in A. baumannii infections, by synthesizing data and knowledge through a systematic review. We searched studies reporting antibiotic resistance in A. baumannii infections using the Medline, Embase, Web of Science, and Cochrane databases from January 2000 to December 2016. Studies were eligible if they investigated and reported antibiotic resistance in A. baumannii infections with inpatients or outpatients in hospital. Our investigation showed a high prevalence of resistance to the common prescribed antibiotics in A. baumannii infections in both OECD (Organization for Economic Co-operation and Development) and non-OECD countries. Strikingly, though OECD countries have substantially lower pooled prevalence of resistance compared to non-OECD countries based on the data during 2006–2016, a further investigation in a time scale disclosed a faster increase in OECD countries during the past 11 years, and currently both of them have a comparable prevalence of resistance (2011–2016). Tigecycline and colistin are still active but their resistances are expected to become common if the preventative measures are not taken. Antibiotic resistance in A. baumannii infection developed fast and is a crisis for both OECD and non-OECD countries. A “post-antibiotic era” for A. baumannii infection is expected in the next 10–20 years without immediate actions from pharmaceutical companies and governments.
机译:由于抗生素耐药性的出现和广泛传播,鲍曼不动杆菌是最具挑战性的医院病原体之一。我们旨在通过系统综述综合数据和知识,对鲍曼不动杆菌感染的全球抗生素耐药性进行首次分析。我们使用Medline,Embase,Web of Science和Cochrane数据库检索了2000年1月至2016年12月报告鲍曼不动杆菌感染的抗生素耐药性的研究。如果研究和报告了住院或门诊患者对鲍曼不动杆菌感染的耐药性,则该研究是合格的。在医院。我们的调查显示,在OECD(经济合作与发展组织)和非OECD国家中,鲍曼不动杆菌对常见处方抗生素的耐药性很高。令人惊讶的是,尽管根据2006-2016年的数据,与非经合组织国家相比,经合组织国家的抗药性普遍水平大大低于非经合组织国家,但进一步的时间范围调查显示,经合组织国家在过去11年中增长更快,目前他们中的耐药率相当(2011-2016年)。替加环素和粘菌素仍然活跃,但如果不采取预防措施,它们的抗药性将变得普遍。鲍曼不动杆菌感染的抗生素耐药性发展很快,这对经合组织和非经合组织国家都是一个危机。预计在未来10至20年内将出现鲍曼不动杆菌感染的“后抗生素时代”,而制药公司和政府不会立即采取行动。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号